HealthCare Global Enterprises (HCG), a leading name in cancer care in India, has announced a significant research collaboration with Trucan Diagnostics , a pioneering startup specialising in advanced cancer diagnostics. The partnership aims to validate innovative diagnostic tests designed to enhance the detection of primary and recurrent/metastatic cancers and improve therapy response prediction and treatment monitoring.
The collaboration focuses on conducting validation studies on Trucan's next-generation cancer diagnostic tests, which leverage advanced techniques such as next-generation sequencing and biomarker-driven diagnostics. These tests aim to provide precise cancer detection, enable pre-treatment response predictions, and monitor treatment efficacy in patients undergoing chemotherapy or targeted therapies.
The novel biomarker-driven methods being developed by Trucan are expected to significantly enhance current diagnostic approaches. By accurately predicting individual therapy responses, these tools promise to help oncologists personalise treatment plans, reduce ineffective therapies, and lower treatment costs while improving patient outcomes.
Dr. B. S. Ajaikumar, Executive Chairman of HCG, highlighted the significance of the partnership, stating, "At HCG, innovation and compassion drive our mission in the fight against cancer. This collaboration with Trucan Diagnostics represents a pivotal step in advancing India’s precision oncology capabilities. Through these next-generation tools developed at our Genomics laboratory at Triesta Sciences, we aim to enhance detection and enable personalised treatment planning, ultimately improving survival rates and quality of life for patients."
Dr. Raman Govindarajan, Founder and CEO of Trucan Diagnostics, added, "This partnership with HCG provides a unique opportunity to validate our novel diagnostic solutions in a real-world setting. We are optimistic that our collaboration will significantly contribute to advancing precision oncology and improving patient care and outcomes."
